| Amaya, Jorge Perez |
NCT04511702: Infusion Duration Study To Assess Tolerability of Pegloticase Administered With a Shorter Infusion Duration in Subjects With Uncontrolled Gout Receiving Methotrexate |
|
|
| Completed | 4 | 191 | US | Pegloticase with MTX, Methotrexate | Amgen | Chronic Uncontrolled Gout, Gout, Uncontrolled Gout | 01/24 | 03/24 | | |
NCT06229145: A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout |
|
|
| Recruiting | 4 | 240 | US | Pegloticase, Methotrexate | Amgen | Gout | 09/25 | 05/26 | | |
NAV3-33, NCT05246280: Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RA |
|
|
| Terminated | 3 | 196 | US | TC99m-tilmanocept, tilmanocept, Lymphoseek | Navidea Biopharmaceuticals | Rheumatoid Arthritis | 07/24 | 07/24 | | |
ANCHOR-1, NCT05274750: Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps |
|
|
| Completed | 3 | 276 | Europe, Canada, Japan, US, RoW | Depemokimab (GSK3511294), Placebo | GlaxoSmithKline | Nasal Polyps | 07/24 | 08/24 | | |
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( ) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, US, RoW | IVA337, Lanifibranor, Placebo | Inventiva Pharma | NASH - Nonalcoholic Steatohepatitis | 09/25 | 09/26 | | |
NCT05636228: Study of INV-102 Ophthalmic Solution in Adults With Acute Infectious Keratoconjunctivitis |
|
|
| Completed | 2 | 93 | US, RoW | INV-102, Vehicle | Invirsa, Inc., Biomedical Advanced Research and Development Authority | Acute Infectious Keratoconjunctivitis | 08/24 | 08/24 | | |
NCT05768113: LAEH Formulation Nasal Spray to Reduce Viral Load |
|
|
| Completed | N/A | 30 | US | | Salvacion USA Inc. | Coronavirus Disease | 10/21 | 01/22 | | |
NCT05569005: Effect of Switching From Cigarette Smoking to THS on Disease Progression in Mild to Moderate COPD Subjects With Chronic Bronchitis Symptoms. |
|
|
| Terminated | N/A | 715 | Europe, Japan, US, RoW | THS use, Tobacco Heating System 3.0, Cigarette, Smoking Abstinence | Philip Morris Products S.A. | COPD, Smoking, Tobacco Use | 09/24 | 09/24 | | |
